Search results for "Ischemic cardiomyopathy"

showing 10 items of 16 documents

Multimodality Imaging in Ischemic Cardiomyopathy

2019

Abstract Ischemic heart disease is the most common heart pathology in medical practice. Proper assessment of the size of myocardium injury and its consequences on the heart function is extremely important both for a correct drug therapy and for interventional approach. Most frequently the left ventricle is affected. The need for accurate evaluation of the impact of left ventricular myocardial damage has led to the development of new imaging techniques and improvement of the existing ones. At the moment the most commonly used imaging method for the assessment of left ventricular function is echocardiography. Cardiac Magnetic Resonance and nuclear tomography are precious imaging techniques as…

03 medical and health sciencesmedicine.medical_specialty0302 clinical medicineIschemic cardiomyopathybusiness.industryInternal medicineCardiologyMedicine030212 general & internal medicineGeneral Medicine030204 cardiovascular system & hematologybusinessMultimodalityActa Universitatis Cibiniensis. Technical Series
researchProduct

Bi-layered polyurethane – Extracellular matrix cardiac patch improves ischemic ventricular wall remodeling in a rat model

2016

As an intervention to abrogate ischemic cardiomyopathy, the concept of applying a temporary, local patch to the surface of the recently infarcted ventricle has been explored from a number of design perspectives. Two important features considered for such a cardiac patch include the provision of appropriate mechanical support and the capacity to influence the remodeling pathway by providing cellular or biomolecule delivery. The objective of this report was to focus on these two features by first evaluating the incorporation of a cardiac extracellular matrix (ECM) component, and second by evaluating the impact of patch anisotropy on the pathological remodeling process initiated by myocardial …

0301 basic medicineMaterials scienceAngiogenesisPolyurethanesBiophysicsMyocardial IschemiaInfarctionBiocompatible MaterialsBioengineeringCeramics and Composite02 engineering and technologyCardiac ECMBiomaterialsExtracellular matrixRats Sprague-Dawley03 medical and health sciencesVentricular Dysfunction LeftAbsorbable ImplantsMaterials TestingmedicineAnimalsMyocardial infarctionCardiac patchIschemic cardiomyopathyTissue ScaffoldsVentricular RemodelingVentricular wallHydrogelsRecovery of Function021001 nanoscience & nanotechnologymedicine.diseaseBiomaterialExtracellular MatrixRatsCompliance (physiology)Electrospun scaffold030104 developmental biologymedicine.anatomical_structureTreatment OutcomeBiophysicVentricleRats Inbred LewMechanics of MaterialsCeramics and CompositesFemale0210 nano-technologyStructure - functionBiomedical engineering
researchProduct

Sca-1+cardiac fibroblasts promote development of heart failure

2018

The causative effect of GM-CSF produced by cardiac fibroblasts to development of heart failure has not been shown. We identified the pathological GM-CSF-producing cardiac fibroblast subset and the specific deletion of IL-17A signaling to these cells attenuated cardiac inflammation and heart failure. We describe here the CD45- CD31- CD29+ mEF-SK4+ PDGFRα+ Sca-1+ periostin+ (Sca-1+ ) cardiac fibroblast subset as the main GM-CSF producer in both experimental autoimmune myocarditis and myocardial infarction mouse models. Specific ablation of IL-17A signaling to Sca-1+ periostin+ cardiac fibroblasts (PostnCre Il17rafl/fl ) protected mice from post-infarct heart failure and death. Moreover, Postn…

0301 basic medicinePathologymedicine.medical_specialtyMyocarditisIschemic cardiomyopathymedicine.medical_treatmentImmunologyInflammationCD29030204 cardiovascular system & hematologyBiologyPeriostinmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCytokineHeart failurecardiovascular systemmedicineImmunology and AllergyMyocardial infarctionmedicine.symptomEuropean Journal of Immunology
researchProduct

2018

ABSTRACT The prototypic protein disulfide isomerase (PDI), encoded by the P4HB gene, has been described as a survival factor in ischemic cardiomyopathy. However, the role of protein disulfide isomerase associated 6 (PDIA6) under hypoxic conditions in the myocardium remains enigmatic, and it is unknown whether the gut microbiota influences the expression of PDI and PDIA6 under conditions of acute myocardial infarction. Here, we revealed that, in addition to the prototypic PDI, the PDI family member PDIA6, a regulator of the unfolded protein response, is upregulated in the mouse cardiomyocyte cell line HL-1 when cultured under hypoxia. In vivo, in the left anterior descending artery (LAD) lig…

0301 basic medicinemedicine.medical_specialtyIschemic cardiomyopathyHypoxia (medical)BiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences030104 developmental biologyEndocrinologyDownregulation and upregulationCell cultureIn vivoInternal medicinecardiovascular systemmedicineUnfolded protein responsecardiovascular diseasesmedicine.symptomGeneral Agricultural and Biological SciencesProtein disulfide-isomeraseLigationBiology Open
researchProduct

Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables.

2012

Downregulation of β1- adrenergic receptors (β1-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established. Another unresolved question is the incidence of these compensatory mechanisms depending on heart failure etiology and treatment. To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α1A, α1B, α1D, β1, β2, and β3) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients wit…

AdultCardiomyopathy DilatedMalemedicine.medical_specialtyGenotypePhysiologyCardiomyopathyMyocardial IschemiaVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansRNA MessengerHeart FailureAnalysis of VarianceEjection fractionIschemic cardiomyopathybiologybusiness.industryBeta adrenergic receptor kinaseMyocardiumDilated cardiomyopathyStroke VolumeStroke volumeMiddle Agedmedicine.diseaseG-Protein-Coupled Receptor KinasesReceptors AdrenergicEndocrinologymedicine.anatomical_structurePhenotypeVentricleSpainHeart failurebiology.proteinCardiologyLinear ModelsFemaleCardiology and Cardiovascular MedicinebusinessCardiomyopathiesAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database.

2013

Background— We aimed to assess in-hospital case fatality and 1-year prognosis in HIV-infected patients with acute myocardial infarction. Methods and Results— From the PMSI (Program de Medicalisation des Systèmes d’informatique) database, data from 277 303 consecutive acute myocardial infarction patients hospitalized from January 1, 2005, to December 31, 2009, were analyzed. Surviving patients were followed up for 1 year after discharge. HIV-infected patients were compared with uninfected patients. Among the cohort, HIV-infected patients (n=608) accounted for 0.22%. All-cause hospital and 1-year mortality rates were lower in the HIV-infected group than in uninfected patients (3.1% versus 8.…

AdultMaleDatabases FactualStatistics as TopicMyocardial InfarctionHIV Infectionscomputer.software_genreCohort StudiesPhysiology (medical)Case fatality ratemedicineHumansMyocardial infarctionMedical Informatics ApplicationsAgedRetrospective StudiesAged 80 and overIschemic cardiomyopathyDatabasebusiness.industryMortality rateRetrospective cohort studyMiddle Agedmedicine.diseaseHospitalizationTreatment OutcomeCohortFemaleMyocardial infarction diagnosisFranceCardiology and Cardiovascular MedicinebusinesscomputerCohort studyCirculation
researchProduct

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

2002

Objective: We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction. Methods: Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60). Results: At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increa…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHemodynamicsBlood PressureSystolic functionVentricular Dysfunction LeftHeart RateInternal medicinemedicineHumansInsulinIn patientInfusion PumpsAgedEjection fractionIschemic cardiomyopathyGlucose insulin potassiumbusiness.industryInsulinStroke VolumeMiddle Agedmedicine.diseaseGlucoseTreatment OutcomeEchocardiographyHeart failureChronic DiseasePotassiumCardiologyCardiomyopathiesCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean Journal of Heart Failure
researchProduct

Ventricular Tachycardia and Early Fibrillation in Patients With Brugada Syndrome and Ischemic Cardiomyopathy Show Predictable Frequency-Phase Propert…

2015

[EN] Background¿ Ventricular fibrillation (VF) has been proposed to be maintained by localized high-frequency sources. We tested whether spectral-phase analysis of the precordial ECG enabled identification of periodic activation patterns generated by such sources. Methods and Results¿Precordial ECGs were recorded from 15 ischemic cardiomyopathy and 15 Brugada syndrome (type 1 ECG) patients during induced VF and analyzed in the frequency-phase domain. Despite temporal variability, induced VF episodes lasting 19.6±7.9 s displayed distinctly high power at a common frequency (shared frequency, 5.7±1.1 Hz) in all leads about half of the time. In patients with Brugada syndrome, phase analysis of …

Adultmedicine.medical_specialty5electrocardiographyInfarctionVentricular tachycardiaTECNOLOGIA ELECTRONICAElectrocardiographyPhysiology (medical)Internal medicinemedicineHumansBrugada syndromeMyocardial infarctioncardiovascular diseasesVentricular fibrillationBrugada syndromeAgedFibrillationIschemic cardiomyopathymedicine.diagnostic_testbusiness.industry106Original ArticlesMiddle Agedmedicine.diseaseventricular fibrillationMyocardial infarctionmyocardial infarctionVentricular TachycardiaAnesthesiaVentricular fibrillationCardiologyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGTachycardia Ventricularmedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiomyopathiesElectrophysiologic Techniques CardiacElectrocardiography
researchProduct

Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary…

1999

Background —We studied the effects of recombinant growth hormone (rhGH) on exercise capacity and cardiac function in patients with ischemic cardiomyopathy. Methods and Results —Seven patients (aged 55±9 years) with mild to moderate congestive heart failure (ejection fraction 31±4%) who were on standard therapy were included. The patients were studied at baseline, after 3 months of rhGH treatment, and 3 months after rhGH discontinuation. Cardiac function was assessed by exercise capacity, right heart catheterization at rest and after submaximal exercise, MRI, echocardiography, and Holter monitoring. When administered at a dose of 2 IU/d, rhGH doubled the serum concentration of insulin-like …

Cardiac function curveMalemedicine.medical_specialtyCardiac outputCardiomyopathyMyocardial IschemiaHemodynamicsVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansVentricular remodelingIschemic cardiomyopathyEjection fractionExercise Tolerancebusiness.industryHuman Growth HormoneHemodynamicsMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryHeart failureCardiologyCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

SYMPTOMATIC ACUTE MYOCARDIAL INFARCTION IN A PATIENT BEARER OF HEART TRANSPLANTATION FOLLOWING ISCHEMIC HEART DISEASE

2008

In 2005 Syeda et al. reported that the major factor limiting the long term of cardiac transplantation is the development of accelerated arteriosclerosis that occurs in the coronary arteries of the cardiac allograft. Transplant arteriosclerosis is characterized by diffuse, uniform, concentric narrowing of the artery by a fibrous proliferation of sub-intima cells. This atherosclerosis was estimate to occur in approximately 50% of patients by 5 years after transplantation. Unfortunately, as a consequence of cardiac denervation, symptoms are often atypical or completely absent. When these are present, the symptoms are those typical of effort angina. Very uncommon is the acute coronary syndrome.…

Heart transplantationmedicine.medical_specialtyAcute coronary syndromeIschemic cardiomyopathybusiness.industrymedicine.medical_treatmentArteriosclerosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryCoronary artery diseaseTransplantationCoronary arteriessurgical procedures operativemedicine.anatomical_structureInternal medicineAtherosclerosis Heart transplantation Coronary artery diseasemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular Medicinebusiness
researchProduct